Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

SUVN-G3031 Safety, Tolerability, and Pharmacokinetics

Start: September 2014
End: August 2015
Enrollment: 64

What Is This Study About?

This Phase I study will investigate the safety, tolerability, and pharmacokinetics of the experimental drug SUVN-G3031 in healthy male subjects.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: 45 Years

Must have:

  • Healthy male aged 18 to 45 years with a Body Mass Index between 18 and 30 kg/m2 (inclusive)

Must NOT have:

  • History of clinically significant disease or disorder that could influence the study volunteer's safety or ability to participate in the study
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Suven Life Sciences Ltd.

Source: ClinicalTrials.gov ID: NCT02342041

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health